This study evaluated adebrelimab (a PD-L1 antibody) plus nab-paclitaxel and carboplatin as perioperative treatment for resectable NSCLC.Eligible patients had resectable stage II-III NSCLCs without driver gene. Patients received neoadjuvant treatment with 3 cycles of intravenous adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (area under the curve 5 mg/mL per min on day 1), of each 21-day cycle before surgical resection, and followed by 16 cycles of adebrelimab (20 mg/kg on day 1 in 3 weeks) adjuvant treatment. The primary endpoint was major pathological response (MPR) per blinded independent pathological review (BIPR).A total of 37 patients were enrolled and received planned neoadjuvant therapy. Thirty-four (91.9%) patients underwent surgery. As of data cutoff on Jan 25, 2022, 19 (51.4%, 95% CI 35.9-66.6) of the 37 patients achieved MPR per BIPR and 11 (29.7%, 95% CI 17.5-45.8) patients achieved pathological complete response. Twenty-six (70.3%, 95% CI 54.2-82.5) patients had an objective response per RECIST v1.1. The 12-month event-free survival (EFS) rate was 77.8% (95% CI 54.1-90.3). Twenty-nine (78.4%) patients had grade ≥3 treatment-related adverse events (AEs) and nine (24.3%) had treatment-related serious AEs. No treatment-related deaths occurred. Grade ≥3 surgery-related AEs within 30 or 90 days after surgery were both reported in 5 (14.7%) patients.Adebrelimab plus nab-paclitaxel and carboplatin as perioperative therapy led to a substantial proportion of MPR and high resectability, with manageable toxicities. Based on the phase 1b results, phase 3 trial was initiated.Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.